Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen  Journal of Cystic Fibrosis  Volume 11, Issue 2, Pages 78-83 (March 2012) DOI: 10.1016/j.jcf.2011.10.003 Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Effect of dornase alfa on markers of inflammation over the 3-year BEAT study [26]. [reprint permission needed] Median neutrophils (% of total cell population), interleukin-8 levels, and elastase activity in bronchoalveolar lavage fluid (BALF) of patients randomized to treatment with dornase alfa or no dornase alfa treatment, at baseline and after 3years. Journal of Cystic Fibrosis 2012 11, 78-83DOI: (10.1016/j.jcf.2011.10.003) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Changes in MMP-9 concentrations in BAL fluid for patients who were untreated (A) or treated with dornase alfa (B) over 18months [24]. Journal of Cystic Fibrosis 2012 11, 78-83DOI: (10.1016/j.jcf.2011.10.003) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Benefit of increasing forced expiratory volume in 1second (FEV1) vs. slowing the rate of decline of FEV1[17]. Journal of Cystic Fibrosis 2012 11, 78-83DOI: (10.1016/j.jcf.2011.10.003) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Mean change in FEV1 from baseline through 96weeks in a study of children with early-stage CF lung disease [9]. Journal of Cystic Fibrosis 2012 11, 78-83DOI: (10.1016/j.jcf.2011.10.003) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 5 Annual rates of decline in FEV1% predicted before and after index PFT in children and adults for the dornase alfa and comparator groups [18]. Journal of Cystic Fibrosis 2012 11, 78-83DOI: (10.1016/j.jcf.2011.10.003) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions